Table 1 Transmission to Tg40 mice of PMCA-treated vCJD urine, PMCA negative control, untreated vCJD urine and vCJD brain homogenate (BH).

From: PMCA-replicated PrPD in urine of vCJD patients maintains infectivity and strain characteristics of brain PrPD: Transmission study

Inoculum

Histology & immunohist.

resPrPD Western blot

Attack rate (posit./tot.)

Incubation periods (dpi)c

Attack rate (posit./tot.)

PrPD type

Incubation periods (dpi)c

PMCA-treated vCJD urinea (1x)b

5/5

679 ± 39

9/9

T2Bd

661 ± 45

PMCA-treated vCJD urine (1:10)b

3/3

718 ± 21

8/8

T2B

713 ± 36*

PMCA of unseeded substrate

0/4

0/718 ± 18

0/9

—

0/673 ± 182

Raw vCJD urine

0/52

0/700 ± 179

0/96

—

0/707 ± 148

vCJD BH 10%

6/6

615 ± 78

9/9

T2B

574 ± 104*

vCJD BH 1%

2/2

657 ± 51

3/3

T2B

648 ± 39

  1. aSix rounds of PMCA have been performed on the resuspended pellet derived from 1 ml urine. bInoculum 1x and 1:10 correspond to undiluted and to diluted 1:10, respectively. cdpi values are express as mean ± standard deviation. dT2B means type 2B and identifies the typical electrophoretic profile of vCJD resPrPD. *Statistically significant difference (p < 0.002) between adjacent T2B values.
Back to article page